Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
982
resultados
Última actualización
30/10/2026 [07:10:00]
Resultados 325 a 350 de 982
Resumen de: WO2026215393A1
The present invention relates to ionizable lipids for use in lipid nanoparticles, lipid nanoparticle formulations comprising these ionizable lipids, alone or in combination with other lipids and/or polymers. The lipid nanoparticles formulations may be formulated with nucleic acids for their delivery to target tissues after administration, in particular after parenteral administration such as intravenous, intramuscular, subcutaneous or intratumoral administration.
Resumen de: WO2026214846A1
The present invention relates to a plurality of nanoparticles comprising crystalline aprepitant. The present invention also relates to a composition comprising the plurality of nanoparticles, a process for producing the composition, and to the plurality of nanoparticles or composition for use in medical methods.
Resumen de: WO2026215899A1
The present invention aims to develop highly efficient lipid-based, drug/gene delivery nano- formulations using glycolipids (GL) and phospholipids (PL) isolated from crude rice bran gum obtained from rice bran oil refinery. Present invention shows that formulations carrying cationic lipid such as D1 with or without PL and cholesterol showed greater penetration through the blood-brain-barrier compared to standard DOPC : Chol formulation. Further supplementation of minute quantity of GL to each formulation enhanced the permeation and retention of respective nano-formulations in mice brains. Moreover, formulations carrying both GL & PL and with or without D1 showed efficient gene transfection in brain cancer cells. Additionally, GL/PL carrying formulations with or without D1 encapsulating hydrophobic anticancer drug, docetaxel showed efficient antitumor effect. Replacing synthetic lipids with natural mixtures of GL/PL reduces cost of production, increases biological output as well as provide value-addition to rice bran gums, helping in overall sustainability of the industry.
Resumen de: WO2026217888A1
Compositions including a nucleotide sequence as set forth in SEQ ID NO: 1 and/or having 95% homology to SEQ ID NO:1, more preferably having 99% homology to SEQ ID NO: 1 wherein each uracil loci in SEQ ID NO: 1 has been substituted with 5-Methoxyuridine (5 MOU) and/or N1-Methylpseudouridine (N1). A method of treating and/or preventing human erectile dysfunction in a subject in need thereof by (a) contacting human penile cells with a composition having a nucleotide sequence as set forth in SEQ ID NO: 1 and/or having 95% homology to SEQ ID NO:1, more preferably having 99% homology to SEQ ID NO: 1 wherein each uracil loci in SEQ ID NO: 1 has been substituted with 5-Methoxyuridine (5 MOU) and/or N1-Methylpseudouridine (N1 ).
Resumen de: WO2026217959A1
The present disclosure provides, for instance, methods and compositions for targeting one or more SRC family kinases. In some embodiments, the composition is an RNA duplex. In some embodiments, the RNA duplex is comprised in a lipid nanoparticle. The present disclosure also provides, for instance, methods and compositions for treating cancer, e.g., breast cancer or ovarian cancer. In some embodiments, the cancer is resistant or refractory to a taxane drug.
Resumen de: KR20260150364A
0001a 광 반응성 나노 플랫폼이 개시되어 있다. 이 개시된 광 반응성 나노 플랫폼은 하이드록시아파타이트 나노입자; 하이드록시아파타이트 나노입자에 도핑된 금속 이온; 및 하이드록시아파타이트 나노입자 표면에 결합된 표적화 리간드 및 광감응제를 포함한다.
Resumen de: WO2026215538A1
The present invention refers to the medical field. Particularly, it refers to a chitosan-based nanocapsule system for use in the prophylactic treatment of an infection caused by a respiratory pathogen, preferably an enveloped respiratory virus, wherein the nanocapsule system is administered intranasally.
Resumen de: WO2026216848A1
The present invention relates to targeting ligand-expressing enveloped virus-like particles (VLPs) and, specifically, to targeting ligand-expressing enveloped VLPs wherein a targeting ligand is fused to an envelope protein among proteins constituting the VLPs, the targeting ligand is expressed on the surface of the VLPs and is located at an ectodomain on the N-terminal side of the envelope protein, and a carrier is included inside the VLPs. In particular, when loaded with a photosensitizer such as KillerRed, the VLPs can significantly improve photodynamic therapy (PDT) efficiency through the generation of target cell-specific reactive oxygen species (ROS) and simultaneously induce immunogenic cell death (ICD) accompanied by calreticulin exposure and ATP release, and thus can be effectively used for tumor-targeted therapy and antitumor immunotherapy.
Resumen de: WO2026217958A1
The present disclosure provides, for instance, methods and compositions for targeting one or more of CDK4, CDK6, and HIF1A. The present disclosure also provides, for instance, methods and compositions for treating cancer, e.g., breast cancer, colorectal cancer, or brain cancer, using a lipid nanoparticle composition described herein. In some embodiments, the lipid nanoparticle is directly injected into a solid tumor.
Resumen de: WO2020023594A1
An extracellular vesicle includes an exogenous therapeutic component. The exogenous therapeutic component can include a therapeutic polypeptide, a polynucleotide that encodes a therapeutic polypeptide, a therapeutic nucleic acid, or a therapeutic agent. In some embodiments, the extracellular vesicle includes an exosome or purified exosome product (PEP).
Resumen de: WO2019157282A1
The present disclosure relates to methods for treating Celiac Disease using tolerizing immune modifying particles that encapsulate antigenic material from the gliadin protein or other related proteins.
Resumen de: AU2026242118A1
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2019/067992 A1 04 April 2019 (04.04.2019) WIPO|PCT (51) International Patent Classification: Published: C12N 15/113 (2010.01) A61K 9/127 (2006.01) with international search report (Art. 21(3)) C12N 15/88 (2006.01) A61K 31/7088 (2006.01) before the expiration of the time limit for amending the C12N 9/22 (2006.01) claims and to be republished in the event of receipt of (21) International Application Number: amendments (Rule 48.2(h)) PCT/US2018/053559 (22) International Filing Date: 28 September 2018 (28.09.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/566,240 29 September 2017 (29.09.2017) US (71) Applicant: INTELLIA THERAPEUTICS, INC. US/US; 40 Erie Street, Cambridge, MA 02139 (US). (72) Inventors: WOOD, Kristy, M.; 34 Earle Road, Welles- ley, MA 02481 (US). GARDNER, Noah, Paul; 41 Mc- Clellan Road, Sutton, MA 01590 (US). SHAH, Ruchi, Rudraprasad; 90 Riverpath Drive, Apartment 19, Fram- ingham, MA 01701 (US). SCULLY, Stephen, S.; 91 Slade Street, Belmont, MA 02478 (US). MAJZOUB, Ramsey; 1 Longfellow Place, #716, Boston, MA 02114 (US). (74) Agent: BENCIVENGA, Nicholas, E.; Finnegan, Hender- son, Farabow, Garrett & Dunner, LLP, 901 New York Av- enue, NW, Washington, DC 20001 (US). (81) Designated States (unle
Resumen de: US2021299234A1
0001 Embodiments are directed to: (i) neutrophil secreted factors that have the capacity to kill a broad range of cancer cells without affecting the viability of non-cancer cells. Two neutrophil killing factors have been identified by the inventors: (1) eosinophil cationic protein (ECP) and (2) neutrophil elastase (ELANE); or (ii) therapeutic compositions that include CD95 degrading polypeptide components and methods of treating cancer with the same.
Resumen de: US20260315516A1
0000 The present invention relates to methods for producing aqueous compositions comprising particles including complexes of polyinosinic-polycytidylic acid poly(I:C) and a water-soluble, linear polyalkyleneimine having defined molecular weight and polydispersity characteristics. In certain embodiments, the poly(I:C) has a selected distribution of double-stranded RNA lengths. The particles can be formed at a nitrogen-to-phosphorus molar ratio within a specified range to control particle formation. The disclosed methods generally comprise separately providing aqueous solutions of the poly(I:C) and the polyalkyleneimine and combining the respective solutions in a mixing chamber under controlled flow and mixing conditions to generate particles typically having a submicron size distribution and a defined z-average diameter as measured by dynamic light scattering according to established standards. In some embodiments, excipients such as sugars are included in the compositions and filtration and/or centrifugation steps are employed to further control particle size, polydispersity and stability.
Resumen de: WO2026216916A1
The present invention relates to a composition for treating severe fever with thrombocytopenia syndrome, the composition comprising mRNA of a human monoclonal antibody against SFTSV. The composition according to the present invention increases the survival rate of SFTSV-infected mice and helps in quickly recovering from organ failure, and thus can be used for SFTSV treatment.
Resumen de: WO2026215779A1
The present invention relates to plant vesicles obtained from Eruca Sativa, food supplements comprising them and their uses in maintaining intestinal well-being, in restoring the diversity of the intestinal microbiota in a subject affected by intestinal dysbiosis, in the prevention and/or treatment of obesity, cerebral senescence and the overall decline in neurocognitive functions caused by neuroinflammation.
Resumen de: WO2026217909A1
Provided herein are compositions and methods for generating mucosal immunity against a pathogen or cancer cell. In particular, provided herein are circular RNA based vaccines formulated for pulmonary delivery and the use of such vaccines to generate mucosal immunity for disease prophylaxis and therapy (e.g., against respiratory viruses and lung-residing cancers).
Resumen de: WO2026213647A1
Described herein are functionalised particles, comprising particle shells comprising a plurality of projections extending outwardly therefrom, wherein the functionalised particles comprise one or more metal complexes adsorbed thereon and one or more basic functional groups and wherein the functionalised particles are at least partially coated with a biological molecule, as well as methods relating to same, and uses thereof.
Resumen de: KR20260150583A
본 발명은 표적 리간드 발현 외피형 바이러스 유사입자에 관한 것으로서, 구체적으로 바이러스 유사입자(Virus-Like Particle, VLP)를 구성하는 단백질 중 외피 단백질에 표적리간드가 융합되고, 상기 표적 리간드는 상기 바이러스 유사입자의 표면에 발현되고 상기 외피 단백질의 N-말단 측 세포 외부 돌출부위(ectodomain)에 위치하며, 상기 바이러스 유사입자의 내부에는 담지체가 포함되는 것을 특징으로 하는, 표적 리간드 발현 외피형 바이러스 유사입자에 관한 것이다. 특히 내부에 킬러레드(KillerRed) 등의 광감작제를 탑재할 경우, 표적 세포 특이적인 활성 산소(ROS) 생성을 통한 광역학 치료(PDT) 효율을 유의미하게 향상시킬 수 있으며, 동시에 칼레티쿨린 노출 및 ATP 방출을 동반하는 면역원성 세포 사멸(ICD)을 유도할 수 있어 종양 표적 치료 및 항종양 면역 치료에 유용하게 활용될 수 있다.
Resumen de: US20260315595A1
A system for the physical manipulation of free magnetic rotors in a circulatory system using a remotely placed magnetic field-generating stator is provided. In one embodiment, the invention relates to the control of magnetic particles in a fluid medium using permanent magnet-based or electromagnetic field-generating stator sources. Such a system can be useful for increasing the diffusion of therapeutic agents in a fluid medium, such as a human circulatory system, which can result in substantial clearance of fluid obstructions, such as vascular occlusions, in a circulatory system resulting in increased blood flow. Examples of vascular occlusions targeted by the system include, but are not limited to, atherosclerotic plaques, including fibrous caps, fatty buildup, coronary occlusions, arterial stenosis, restenosis, vein thrombi, arterial thrombi, cerebral thrombi, embolisms, hemorrhages, other blood clots, and very small vessels.
Resumen de: WO2026215197A1
The present disclosure relates to compositions that include oily nanocores containing oligo/polynucleotides, e.g., in the form of nano-emulsions, for the prevention or treatment of diseases. In particular, it relates to an oil-in-water nano-emulsion composition comprising : (a) an ionizable cationic lipid, (b) a permanently cationic lipid, (c) an oil, (d) a surfactant, (e) an active ingredient comprising an oligonucleotide and/or a polynucleotide, (f) an aqueous medium, optionally comprising, at least one of (g) a PEG-lipid, (h) an amphiphilic polymer, and (i) a hydrophilic polymer, and, further optionally comprising, (j) an additional lipid selected from a phospholipid, a fatty acid, a fatty acid derivative, and a fatty amine, wherein the nano- emulsion composition comprises from 8.0 to 60.0 mol% of ionizable cationic lipid (a), from 8.0 to 40.0 mol% of permanently cationic lipid (b), and a molar ratio of (a) to (b) from 1:1 to 5:1, preferably ratio of (a) to (b) from 1:1 to 3:1 or 1:1 to 4:1, wherein the mol % is with respect to the total mols of (a), (b), (c), (d), and, if present, (g) and (j). The present disclosure further relates to said composition in lyophilized form, a reconstructed nano-emulsion from the lyophilized composition, formulations comprising said compositions and a pharmaceutically acceptable excipient, to methods for the preparation of said compositions, and to medical uses of said compositions and formulations for the treatment or prevention of a diseas
Resumen de: WO2026215131A1
Disclosed herein are ionizable lipids defined as compounds of Formula (I) or stereoisomers, tautomers, hydrates, solvates or salts thereof. Also disclosed are lipid nanoparticles comprising said compounds; pharmaceutical compositions comprising a plurality of lipid nanoparticles comprising said compounds, as well as methods for delivering a nucleic acid segment comprising administering a plurality of lipid nanoparticles comprising said compound, and a nucleic acid segment.
Resumen de: WO2026215132A1
Disclosed herein are ionizable lipids defined as compounds of Formula (I) or stereoisomers, tautomers, hydrates, solvates or salts thereof. Also disclosed are lipid nanoparticles comprising said compounds; pharmaceutical compositions comprising a plurality of lipid nanoparticles comprising said compounds, as well as methods for delivering a nucleic acid segment comprising administering a plurality of lipid nanoparticles comprising said compound, and a nucleic acid segment.
Resumen de: US20260315407A1
The present invention provides apparatus, systems, and methods for continuous manufacturing of RNA.
Nº publicación: US20260315437A1 15/10/2026
Solicitante:
AADI BIOSCIENCE INC [US]
AADI Bioscience, Inc.
Resumen de: US20260315437A1
0000 The present application, in certain aspects, pertains to methods and compositions for the treatment of a hormone-dependent cancer (such as an endometrial cancer (e.g., endometrioid endometrial cancer) or hormone-receptor positive breast cancer), using a composition comprising nanoparticles comprising sirolimus and an albumin in combination with an estrogen suppressor (such as letrozole or fulvestrant).
BOPI
Sede Electrónica
